Multivariate optimization of formulation and process variables influencing physico-mechanical characteristics of site-specific release isoniazid pellets

International Journal of Pharmaceutics

Volumn 388, Issue 1-2, 2010, Pages 64-72

  Pund, Swati ^a   Joshi, Amita ^a   Vasu, Kamala ^a   Nivsarkar, Manish ^a   Shishoo, Chamanlal ^a  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

Author keywords

Full factorial design; Isoniazid; Multiple response optimization; Pellets; Physico mechanical characteristics

Indexed keywords

ISONIAZID;

ARTICLE; CHEMICAL BINDING; DISSOLUTION; DRUG COATING; DRUG FORMULATION; DRUG GRANULATION; DRUG PELLET; DRUG RELEASE; LIQUID; MECHANICAL STRESS; MOISTURE; MULTIVARIATE ANALYSIS; PHYSICAL CHEMISTRY; POROSITY; PRIORITY JOURNAL; SPHERONIZATION;

ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; ISONIAZID; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; PARTICLE SIZE; POROSITY; SOLUBILITY; WATER;

EID: 76549123871     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.12.034     Document Type: Article

References (41)

1. Akhgari A., Garekani H.A., Sadeghi F., and Azimaie M. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Int. J. Pharm. 305 (2005) 22-30
2. Almeida-Prieto S., Blanco-Méndez J., and Otero-Espinar F.J. Microscopic image analysis techniques for the morophological characterization of pharmaceutical particles: influence of the software and the factor algorithms used in the shape factor estimation. Eur. J. Pharm. Biopharm. 67 (2007) 766-776
3. Becker C., Dressman J.B., Amidon G.L., Junginger H.E., Kopp S., Midha K.K., Shah V.P., Stavchansky S., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. J. Pharm. Sci. 96 (2007) 522-531
4. Chopra R., Newton J.M., Alderborn G., and Podczeck F. Preparation of pellets of different shape and their characterization. Pharm. Dev. Technol. 6 (2001) 495-503
5. Costa P., and Lobo J.M.S. Modelling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13 (2001) 123-133
6. Furlanetto S., Maestrelli F., Orlandini S., and Mura P. Optimization of dissolution test precision for a ketoprofen oral extended-release product. J. Pharm. Biomed. Anal. 32 (2003) 159-165
7. Furlanetto S., Cirri M., Maestrelli F., Corti G., and Mura P. Study of formulation variables influencing the drug release rate from matrix tablet by experimental design. Eur. J. Pharm. Biopharm. 62 (2006) 77-84
8. Ghebre-Sellassie I., and Knoch A. Pelletization techniques. In: Swarbrick J.E. (Ed). Encyclopedia of Pharmaceutical Technology vol. 3 (2007), Informa Healthcare, New York 2651-2663
9. Gómez-Carracedo A., Alvarez-Lorenzo C., Coca R., Martínez-Pacheco R., Concheiro A., and Gómez-Amoza J.L. Fractal analysis of SEM images and mercury intrusion porosimetry data for the microstructural characterization of microcrystalline cellulose-based pellets. Acta Mater. 57 (2009) 295-303
10. Gupta V.K., Assmus M.W., Beckert T.E., and Price J.C. A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables. Int. J. Pharm. 213 (2001) 93-102
11. Hellén L., Yliruusi J., and Kristoffersson E. Process variables of instant granulator and spheronizer: II. Size and size distribution of pellets. Int. J. Pharm. 96 (1993) 205-216
12. Heng P.W.S., and Koo O.M.Y.K. A study of the effects of the physical characteristics of microcrystalline cellulose on performance in extrusion spheronization. Pharm. Res. 18 (2001) 480-487
13. Howard M.A., Neau S.H., and Marvin J.S. PEO and MPEG in high drug load extruded and spheronized beads that are devoid of MCC. Int. J. Pharm. 307 (2006) 66-76
14. Joshi A., Pund S., Nivsarkar M., Vasu K., and Shishoo C. Dissolution test for site-specific release isoniazid pellets in USP apparatus 3 (reciprocating cylinder): Optimization using response surface methodology. Eur. J. Pharm. Biopharm. 69 (2008) 769-775
15. Jover I., Podczeck F., and Newton M. Evaluation, by a statistically designed experiment, of an experimental grade of microcrystalline cellulose, Avicel 955, as a technology to aid the production of pellets with high drug loading. J. Pharm. Sci. 85 (1996) 700-705
16. Kim M., Kim J., You Y., Park H.J., Lee S., Park J., Woo J., and Hwang S. Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology. Int. J. Pharm. 341 (2007) 97-104
17. Koo O.M.Y.K., and Heng P.W.S. The influence of microcrystalline cellulose grade on shape and shape distributions of pellets produced by extrusion-spheronization. Chem. Pharm. Bull. 49 (2001) 1383-1387
18. Kramar A., Turk S., and Vrečer F. Statistical optimization of diclofenac sustained release pellets coated with polymethacrylic films. Int. J. Pharm. 256 (2003) 43-52
19. Kramer J., and Blume H. Biopharmaceutical aspects of multiparticulates. In: Sellassie I.G. (Ed). Multiparticulate Oral Drug Delivery vol. 65 (1994), Marcel Dekker Inc., New York 307-355
20. Lustig-Gustafsson C., Johal H.K., Podczeck F., and Newton J.M. The influence of water content and drug solubility on the formulation of pellets by extrusion and spheronization. Eur. J. Pharm. Sci. 8 (1999) 147-152
21. Mariappan T.T., and Singh S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int. J. Tuberc. Lung Dis. 7 (2003) 797-803
22. Mehta A.M. Evaluation and characterization of pellets. In: Ghebre-Sallassie I. (Ed). Pharmaceutical Pelletization Technology vol. 37 (1989), Marcel Dekker Inc., New York 241-265
23. Melia C.D., Washington N., and Wilson C.G. Advantages and disadvantages of multiparticulate delivery systems. In: Melia C.D., Washington N., and Wilson C.G. (Eds). Multiparticulate Oral Dosage Forms: Technology and Biopharmaceutics (1994), Scottish Academic Press, Edinburgh 135-140
24. Menegola J., Steppe M., and Schapoval E.E.S. Dissolution test for citalopram in tablets and comparison of in vitro dissolution profiles. Eur. J. Pharm. Biopharm. 67 (2007) 524-530
25. ® 974P NF resin made by extrusion-spheronization. Int. J. Pharm. 199 (2000) 129-140
26. Newton J.M., Pinto M.R., and Podczeck F. The preparation of pellets containing a surfactant or a mixture of mono- and di-glycerides by extrusion/spheronization. Eur. J. Pharm. Sci. 30 (2007) 333-342
27. 3 factorial design and the desirability function. Int. J. Pharm. 248 (2002) 51-60
28. Podczeck F., Rahman S.R., and Newton J.M. Evaluation of standardised procedure to assess the shape of the pellets using image analysis. Int. J. Pharm. 192 (1999) 123-138
29. Podczeck F., Knight P.E., and Newton J.M. The evaluation of modified microcrystalline cellulose for the preparation of pellets with high drug loading by extrusion/spheronization. Int. J. Pharm. 350 (2008) 145-154
30. Rastogi R., Sultana Y., Aqil M., Ali A., Kumar S., Chuttani K., and Mishra A.K. Alginate microspheres of isoniazid for oral sustained drug delivery. Int. J. Pharm. 334 (2007) 71-77
31. Rowe R.C., York P., Colbourn E.A., and Roskilly S.J. The influence of pellet shape, size and distribution on capsule filling-a preliminary evaluation of three-dimensional computer simulation using a Monte-Carlo technique. Int. J. Pharm. 300 (2005) 32-37
32. Shishoo C.J., Shah S.A., Rathod I.S., Savale S.S., and Vora M.J. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int. J. Pharm. 228 (2001) 53-67
33. Shishoo C.J., Shah S.A., Rathod I.S., and Savale S.S. Impaired bioavailability of rifampicin from fixed dose combination formulations with isoniazid. Indian J. Pharm. Sci. 63 (2001) 443-449
34. Singh B., Chakkal S., and Ahuja N. Formulation and optimization of controlled release mucoadhesive tablets of Atenolol using response surface methodology. AAPS PharmSciTech. 7 (2006) E3
35. Singh S., Mariappan T.T., Sankar R., Sarda N., and Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int. J. Pharm. 228 (2001) 5-17
36. Sousa J.J., Sousa A., Podczeck F., Newton J.M., and Sousa J.J. Influence of process conditions on drug release from pellets. Int. J. Pharm. 144 (1996) 159-169
37. Sousa A., Podczeck F., and Newton J.M. Factors influencing the physical characteristics of pellets obtained by extrusion-spheronization. Int. J. Pharm. 232 (2002) 91-106
38. Steckel H., and Mindermann-Nogly F. Production of chitosan pellets by extrusion/spheronization. Eur. J. Pharm. Biopharm. 57 (2004) 107-114
39. Toit L.C., Pillay V., and Danckwerts M.P. Tuberculosis chemotherapy: current drug delivery approaches. Respiratory Res. 7 (2006) 118
40. US Pharmacopoeia 30/NF25, 2007a. US Pharmacopoeial Convention, Rockville, MD, pp. 385.
41. US Pharmacopoeia 30/NF25, 2007b. US Pharmacopoeial Convention, Rockville, MD, pp. 282.